Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

PHASE4RECRUITING

The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501), in participants with macular telangiectasia type 2 (MacTel) who previously received the intraocular implant in a Phase 1, Phase 2, or Phase 3 clinical study and have retained at least 1 NT-501 at study entry. In addition, this study will evaluate the safety and efficacy of NT501 in participants who previously underwent the sham procedure in a Phase 3 MacTel clinical study and elect to have NT-501 implanted intraocularly in this Phase 4 study.

Study details:

This extension study consists of 3 arms:. * Arm 1 (Phase 3 Treated Participants' Long-term Follow-up): Arm 1 is to assess the long-term safety and efficacy of NT-501 in participants who received NT-501 in a previous MacTel Phase 3 clinical study (NTMT-03-A or NTMT-03-B) and have retained at least 1 NT-501at study entry. * Arm 2 (Phase 1 and Phase 2 Long-term Follow-up): Similar to Arm 1, Arm 2 is to assess the long-term safety of NT-501 in participants who received NT-501 in a previous MacTel Phase 1 or Phase 2 clinical study (NTMT-01, NTMT-02, or NTMT-01/02E) and have retained at least 1 NT-501 at study entry.

* Arm 3 (Phase 3 Sham to Implant Crossover): Arm 3 will evaluate the safety and efficacy of NT-501 in participants who previously underwent the sham procedure in a Phase 3 MacTel clinical study (NTMT-03-A or NTMT-03-B) and elect to have NT-501 implanted intraocularly in this extension study. Arms 1 and 2 are noninterventional and observational studies. For participants who previously received a single NT-501 implant, the implanted eye is designated the study eye.

For participants who received an NT-501 in both eyes (ie, the first implant received in NTMT-01, NTMT-02, NTMT-01/02E, NTMT-03A, or NTMT-03B, and the second implant received in NTMT-02B), both eyes will be designated as study eyes. Only participants in Arm 3 will receive active intervention during this Phase 4 study. A participant can receive NT-501 in either eye that meets eligibility criteria according to investigator assessment, and in accordance with participant choice.

However, if only 1 eye is eligible for implantation based on all inclusion/exclusion criteria, then that eye will be selected for NT-501 implantation. The eye selected for NT-501 implantation will be designated as the study eye. Regardless of study eye designation, both eyes of each participant in all 3 study arms will be evaluated during the study.

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  1. Male or female adult participants who previously completed an NT-501 MacTel clinical study and: Arm 1: received NT-501 intraocular implant in either Phase 3 study (NTMT-03-A or NTMT-03-B), Arm 2: received NT-501 intraocular implant in the Phase 1 study (NTMT-01), Phase 2 study (NTMT-02), or in the substudy of the Phase 1 and Phase 2 extension study (NTMT-01/02E), Arm 3: underwent the sham procedure in either Phase 3 study (NTMT-03-A or NTMT-03-B)
  2. Participants must have steady fixation in the foveal or parafoveal area and sufficiently clear media for good quality retinal imaging.
  3. Participant or their legally authorized representative must be able to provide written informed consent to participate in the study, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, and local regulations, before initiating any clinical study related procedures.
  4. Arm 3: female participants of childbearing potential must agree to use highly effective contraception.

Exclusion criteria

  1. Participant is medically unable to comply with clinical study procedures or visits.
  2. Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations, and outcome assessments.
  3. Participant has significant corneal or media opacities in the study eye to be implanted.
  4. Participant has evidence of pathologic myopia in the study eye to be implanted.
  5. Participant has any of the following lens opacities in the study eye to be implanted: cortical opacity > standard 3, posterior subcapsular opacity > standard 2, or a nuclear opacity > standard 3 as measured on the Age- Related Eye Disease Study (AREDS) clinical lens grading system.
  6. Participant has undergone lens removal in the study eye to be implanted in the previous 3 months or YAG laser within 4 weeks of the screening/baseline visit.
  7. Participant has evidence of ocular disease in the study eye to be implanted other than MacTel that, in the judgment of the examining physician, may confound the diagnosis, procedures, or outcome of the study (eg. glaucoma, severe nonproliferative or proliferative diabetic retinopathy, uveitis).
  8. Received intravitreal steroid therapy in the study eye to be implanted within the last year.
  9. Received intravitreal anti-vascular endothelial growth factor therapy in the study eye to be implanted within the last 6 months.
  10. Evidence of active exudative intraretinal neovascularization or subretinal neovascularization in the study eye to be implanted, as evidenced by hemorrhage, hard exudate, subretinal fluid, or intraretinal fluid.
  11. Evidence of central serous chorioretinopathy in the study eye to be implanted.
  12. Participant underwent vitrectomy, penetrating keratoplasty, trabeculectomy, or trabeculoplasty in the study eye to be implanted.
  13. A history of ocular herpes virus in the study eye to be implanted.
  14. Participant is on chemotherapy.
  15. Participant is pregnant or breastfeeding.
  16. Participation in any other clinical study of an intervention (drug or device) within 6 months prior to the screening/baseline visit.
  17. A history of malignancy that would compromise survival during the clinical study.

Eligibility

Age eligible for study : NA

Healthy volunteers accepted : No

Gender eligible for study: ALL

Things to know

Study dates

Study start:

Primary completion:

Study completion finish:

study type

Study type

TREATMENT

phase

Phase

    PHASE4

trial

Study ID

NCT06971939

Intervention or treatment

COMBINATION_PRODUCT: NT-501/revakinagene taroretcel-lwey

Conditions

  • Macular Telangiectasia Type 2 (MacTel)
  • Condition: Macular Telangiectasia Type 2 (MacTel)

  • COMBINATION_PRODUCT: NT-501/revakinagene taroretcel-lwey

  • Perth, Australia and more

  • Sponsor: Neurotech Pharmaceuticals

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial?

If you're a clinic or sponsor, you can claim this study

Research sites nearby

Closest Location:

Lion's Eye Institute

Select from list below to view details:

  • Lion's Eye Institute

    Perth, Australia

  • Cerulea

    East Melbourne, Australia

  • Sydney Eye Hospital

    Sydney, Australia

Loading map...

Who is running the clinical trial?

NP

Neurotech Pharmaceuticals

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/ArmIntervention/Treatment
OTHER: Arm 1 (Phase 3 Long-term Follow-up)
  • For participants who received NT-501 (ENCELTO) in a previous Phase 3 study (NTMT-03-A or NTMT-03-B), or for participants who received NT-501 (ENCELTO) in both eyes (i.e. participated in study NTMT-02B) but received the first NT-501 (ENCELTO) implant in a Phase 3 study. No new treatment intervention will be administered. Arm 1 is focused on long term follow-up for participant who already has the ENCELTO implant at time of study screening and enrollment.
Combination Product: NT-501/revakinagene taroretcel-lwey
    OTHER: Arm 2 (Phase 1 and Phase 2 Long-term Follow-up)
    • For participants who received NT-501 (ENCELTO) in a previous Phase 1 study (NTMT-01), Phase 2 study (NTMT-02), in the sub study of Phase 1 and Phase 2 extension study (NTMT-01/02E), or for participants who received NT-501 (ENCELTO) in both eyes (i.e. participated in study NTMT-02B) but received the first NT-501 (ENCELTO) implant in a Phase 1 or Phase 2 study. No new treatment intervention will be administered. Arm 2 is focused on long term follow-up for participant who already has the ENCELTO implant at time of study screening and enrollment.
    Combination Product: NT-501/revakinagene taroretcel-lwey
      EXPERIMENTAL: Arm 3 (Phase 3 Sham to Implant Crossover)
      • For participants who underwent Sham procedure in either Phase 3 study (NTMT-03-A or NTMT-03-B) and will receive NT-501 in this study.
      Combination Product: NT-501/revakinagene taroretcel-lwey

        What is the study measuring?

        Primary Outcome

        MeasureDescriptionTime Frame
        Incidence of ocular and nonocular adverse events (AEs) and serious adverse events (SAEs)Incidence of ocular and nonocular adverse events (AEs) and serious adverse events (SAEs)Baseline and annually for up to 5 yrs for Arms 1 and 2 and baseline, perioperative, and annually for up to 5 yrs for Arm 3 participants
        Percentage of participants with a loss of 15 letters or more in best corrected visual acuity (BCVA) compared to presurgery baseline BCVAPercentage of participants with a loss of 15 letters or more in best corrected visual acuity (BCVA) compared to presurgery baseline BCVA using the Early Treatment Diabetic Retinopathy Study (ETDRS) distance chartBaseline and annually for up to 5 yrs for Arms 1 and 2 and baseline, perioperative, and annually for up to 5 yrs for Arm 3 participants

        Secondary Outcome

        MeasureDescriptionTime Frame
        Change from presurgery baseline in ellipsoid zone (EZ) area lossChange from presurgery baseline in ellipsoid zone (EZ) area loss as measured by en face spectral domain optical coherence tomography (SD-OCT) for both eyesBaseline and annually for up to 5 yrs for Arms 1 and 2 and baseline, perioperative, and annually for up to 5 yrs for Arm 3 participants
        Change from presurgery baseline in BCVAChange from presurgery baseline in BCVA using the ETDRS distance chart for both eyesBaseline and annually for up to 5 yrs for Arms 1 and 2 and baseline, perioperative, and annually for up to 5 yrs for Arm 3 participants
        Change from presurgery baseline in aggregate retinal sensitivityChange from presurgery baseline in aggregate retinal sensitivity as measured by microperimetry within the EZ line break area for both eyesBaseline and annually for up to 5 yrs for Arms 1 and 2 and baseline, perioperative, and annually for up to 5 yrs for Arm 3 participants
        Change from presurgery baseline in monocular reading speedChange from presurgery baseline in monocular reading speed for both eyesBaseline and annually for up to 5 yrs for Arms 1 and 2 and baseline, perioperative, and annually for up to 5 yrs for Arm 3 participants
        Change from presurgery baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25)Change from presurgery baseline in NEI-VFQ-25 near activities subscale score. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively.Baseline and annually for up to 5 yrs for Arms 1 and 2 and baseline, perioperative, and annually for up to 5 yrs for Arm 3 participants
        Are you running this trial?If you're a clinic or sponsor, you can claim this study.

        References

        Clinical Trials Gov: Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

        Other trials to consider

        Loading suggested trials...

        Top searched conditions